Last reviewed · How we verify
Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes
This study is aimed at calculating the incidence of nonalcoholic fatty liver disease (NAFLD), non- alcoholic steatohepatitis (NASH) cirrhosis and advanced fibrosis in patients with type 2 diabetes in China, evaluating the diagnostic efficacy of FibroTouch for hepatic steatosis and fibrosis in these patients, analyzing the long-term prognosis and screening potential risk factors in patients with both type 2 diabetes and NAFLD. This study will use FibroTouch to screen NAFLD, NASH cirrhosis and advanced fibrosis in patients with type 2 diabetes, compare the results with liver tissue biopsy to assess the clinical value of FibroTouch for the screening of NAFLD in diabetics, then investigate the clinical significance of FibroTouch in assessing the long-term prognosis of patients with diabetes and NAFLD in a prospective cohort, screen risk factors for diabetes with NAFLD and advanced fibrosis.
Details
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Status | UNKNOWN |
| Enrolment | 10000 |
| Start date | Sat May 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Type 2 Diabetes Mellitus
- Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
- FibroTouch
Countries
China